DOP2018000014A - Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina - Google Patents

Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina

Info

Publication number
DOP2018000014A
DOP2018000014A DO2018000014A DO2018000014A DOP2018000014A DO P2018000014 A DOP2018000014 A DO P2018000014A DO 2018000014 A DO2018000014 A DO 2018000014A DO 2018000014 A DO2018000014 A DO 2018000014A DO P2018000014 A DOP2018000014 A DO P2018000014A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
sortiline
progranulin
bind
inhibit
Prior art date
Application number
DO2018000014A
Other languages
English (en)
Inventor
John Malik Ibrahim
B Stavenhagen Jeffrey
Egebjerg Jan
Van Den Brink Edward
Parren Paul
Christian Biilmann Rønn Lars
Christensen Søren
Gerritsen Arnout
De Jong Rob
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of DOP2018000014A publication Critical patent/DOP2018000014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-sortilina que se ha encontrado que son útiles en la corrección de un nivel deficiente de progranulina (PGRN). En particular, pueden usarse estos anticuerpos en el tratamiento de demencia frontotemporal (DFT) y esclerosis lateral amiotrófica (ELA).
DO2018000014A 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina DOP2018000014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
DOP2018000014A true DOP2018000014A (es) 2018-04-15

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000014A DOP2018000014A (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina

Country Status (31)

Country Link
US (5) US10479835B2 (es)
EP (1) EP3322726A1 (es)
JP (2) JP6979397B2 (es)
KR (1) KR20180030045A (es)
CN (3) CN114478775A (es)
AR (1) AR105335A1 (es)
AU (1) AU2016292980B2 (es)
BR (1) BR112018000771A2 (es)
CA (1) CA2989739A1 (es)
CL (2) CL2018000092A1 (es)
CO (1) CO2017012988A2 (es)
CR (1) CR20180002A (es)
DO (1) DOP2018000014A (es)
EA (1) EA201890038A1 (es)
EC (1) ECSP18002725A (es)
GB (1) GB201512215D0 (es)
HK (1) HK1254356A1 (es)
IL (1) IL256503B (es)
JO (1) JO3710B1 (es)
MA (1) MA42440A (es)
MX (1) MX2018000506A (es)
NI (1) NI201800007A (es)
PE (1) PE20181014A1 (es)
PH (1) PH12018500100A1 (es)
RU (1) RU2735639C2 (es)
SV (1) SV2018005613A (es)
TN (1) TN2017000534A1 (es)
TW (1) TWI760305B (es)
UA (1) UA125136C2 (es)
WO (1) WO2017009327A1 (es)
ZA (1) ZA201708613B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211980T1 (hr) * 2015-04-07 2022-04-01 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
HUE061841T2 (hu) * 2018-07-13 2023-08-28 Alector Llc Anti-sortilin antitestek és felhasználásuk módszerei
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ES2228467T3 (es) 1999-02-03 2005-04-16 Biosante Pharmaceuticals, Inc. Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso.
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
LT3225251T (lt) 2006-12-21 2020-04-10 H. Lundbeck A/S Proneurotrofinų veiklos moduliavimas
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US8377701B2 (en) 2008-04-27 2013-02-19 H. Lundbeck A/S Specific ligands to sortilin
EP2293667A4 (en) 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10 (IL-10R) RECEPTOR ANTIBODIES AND METHODS OF USE
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102439041B (zh) * 2008-12-19 2016-05-04 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
WO2014071131A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
HRP20211980T1 (hr) 2015-04-07 2022-04-01 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
HUE061841T2 (hu) 2018-07-13 2023-08-28 Alector Llc Anti-sortilin antitestek és felhasználásuk módszerei

Also Published As

Publication number Publication date
RU2735639C2 (ru) 2020-11-05
US20230159643A1 (en) 2023-05-25
JP6979397B2 (ja) 2021-12-15
CR20180002A (es) 2018-04-09
UA125136C2 (uk) 2022-01-19
ZA201708613B (en) 2021-03-31
IL256503A (en) 2018-02-28
US20170267761A1 (en) 2017-09-21
JO3710B1 (ar) 2021-01-31
US11548950B2 (en) 2023-01-10
HK1254356A1 (zh) 2019-07-19
SV2018005613A (es) 2018-02-23
CL2020002468A1 (es) 2021-01-29
EA201890038A1 (ru) 2018-06-29
CN114478775A (zh) 2022-05-13
GB201512215D0 (en) 2015-08-19
TW201702273A (zh) 2017-01-16
RU2018100824A (ru) 2019-08-13
TWI760305B (zh) 2022-04-11
AU2016292980B2 (en) 2022-10-06
CO2017012988A2 (es) 2018-05-21
IL256503B (en) 2022-02-01
BR112018000771A2 (pt) 2018-09-25
ECSP18002725A (es) 2018-03-31
US20180305455A1 (en) 2018-10-25
US10479835B2 (en) 2019-11-19
US20210269524A1 (en) 2021-09-02
EP3322726A1 (en) 2018-05-23
PE20181014A1 (es) 2018-06-26
US10428147B2 (en) 2019-10-01
RU2018100824A3 (es) 2020-01-17
PH12018500100A1 (en) 2018-07-30
CL2018000092A1 (es) 2018-07-06
MX2018000506A (es) 2018-05-11
MA42440A (fr) 2018-05-23
TN2017000534A1 (en) 2019-04-12
KR20180030045A (ko) 2018-03-21
NI201800007A (es) 2018-10-18
JP2022003058A (ja) 2022-01-11
US10889650B2 (en) 2021-01-12
JP2018529635A (ja) 2018-10-11
CN114478774A (zh) 2022-05-13
CA2989739A1 (en) 2017-01-19
AR105335A1 (es) 2017-09-27
WO2017009327A1 (en) 2017-01-19
CN107849135A (zh) 2018-03-27
US20200190188A1 (en) 2020-06-18
AU2016292980A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
DOP2018000014A (es) Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina
MD3307288T2 (ro) Compoziții care conțin tulpini bacteriene
MD3549592T2 (ro) Compoziții care conţin tulpini bacteriene
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
MD3360558T2 (ro) Compoziții care cuprind tulpini bacteriene
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201791711A1 (ru) Антитела к транстиретину
EA201791710A1 (ru) Антитела к транстиретину
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
ECSP20002935A (es) Agentes, usos y métodos para el tratamiento
EA202091989A1 (ru) Способы лечения язвенного колита
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201991471A1 (ru) Способы введения гепсидина